People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Other Technology, Other Health Care, Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NLX Inc. | — | Other Technology | Series A | $21.8M | $78.8M | 2024 |
| VenoStent, Inc. | — | Other Health Care | Series B | $19.1M | $142.0M | 2023 |
| UrbanFox Holdings Inc. | — | Other | Series A | $7.5M | $28.7M | 2025 |
| Lindy Biosciences, Inc. | — | Biotechnology | Seed | $5.7M | $9.8M | 2024 |
Joel Whitley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joel Whitley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Crutchfield | 1 | 5 |
| Sreekar Gadde | 1 | 4 |
| Karen LeVert | 1 | 2 |
| Omar Flores | 1 | 1 |
| Deborah Bitterfield | 1 | 1 |
| Andrei Papancea | 1 | 1 |
| John Brian Dawson | 1 | 1 |
| Lauren Glatter | 1 | 1 |
| Timothy Boire | 1 | 1 |
| Jim Monsor | 1 | 1 |
| Geoffrey Lucks | 1 | 1 |
| Kulika Weizman | 1 | 1 |
| Daniel Loftus | 1 | 1 |
| Patrick Pinschmidt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.